Patrick Chhatwal

Learn More
BACKGROUND & AIMS Interferon-based therapies for hepatitis C virus (HCV) infection are limited by side effects and incomplete response rates, particularly among transplant recipients. We screened a library of plant-derived small molecules to identify HCV inhibitors with novel mechanisms. METHODS We isolated phenolic compounds from Marrubium peregrinum L(More)
BACKGROUND Hepatitis C virus (HCV) patients with high serum levels of bile acids (BAs) respond poorly to IFN therapy. BAs have been shown to increase RNA-replication of genotype 1 but not genotype 2a replicons. Since BAs modulate lipid metabolism including lipoprotein secretion and as HCV depends on lipids and lipoproteins during RNA-replication, virus(More)
Antiviral CD8(+) T cells are a key component of the adaptive immune system against hepatitis C virus (HCV). For the development of immune therapies, it is essential to understand how CD8(+) T cells contribute to clearance of infection and why they fail so often. A mechanism for secondary failure is mutational escape of the virus. However, some substitutions(More)
UNLABELLED Hepatitis C virus (HCV) particles associate with lipoproteins and infect cells by using at least four cell entry factors. These factors include scavenger receptor class B type I (SR-BI), CD81, claudin 1 (CLDN1), and occludin (OCLN). Little is known about specific functions of individual host factors during HCV cell entry and viral domains that(More)
476 www.thelancet.com/infection Vol 17 May 2017 2 Vonberg RP, Gastmeier P. Quality of outbreak descriptions in medical literature. Lancet Infect Dis 2007; 7: 699–700. 3 Vonberg RP, Weitzel-Kage D, Behnke M, et al. Worldwide Outbreak Database: the largest collection of nosocomial outbreaks. Infection 2011; 39: 29–34. outbreak reports of interest. We only(More)
  • 1